Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
34 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
3 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
144.6 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
38
38 articles ont été cités au moins 38fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
10 750
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
274
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
97
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Hôpital Privé Jean Mermo
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer
2026ArticleNature
ALTOPANC: Local ablative therapies in oligometastatic pancreatic adenocarcinoma—A bi-national French-Belgian retrospective study.
2026ArticleJournal of Clinical Oncology
Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study
2025ArticleJNCI: Journal of the National Cancer Institute
Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study
2025ArticleOncologist
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials
2025ArticleJournal of Clinical Oncology
Rectal cancer - French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR, and GRECCAR)
2025ArticleDigestive and Liver Disease
Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prospective multicentre study
2024ArticleEBioMedicine
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer
2024ArticleOncologist
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CABINET DU DR PASCAL ARTRU
HOPITAL PRIVE JEAN MERMOZ 55 AVENUE JEAN MERMOZ, 69373 LYON CEDEX 08
CLINIQUE DU PARC LYON
155 BD STALINGRAD, 69006 LYON
HOPITAL PRIVE DE L'EST LYONNAIS (HPEL)
140 R ANDRE LWOFF, 69800 ST PRIEST
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The New England journal of medicine · 2018
JAMA oncology · 2022
ImportanceEarly results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified FOLFIRINOX vs gemcitabine in patients with resected pancreatic ductal adenocarcinoma; mature data are now available.ObjectiveTo report 5-year outcomes and explore prognostic factors for overall survival.Design, Setting, and ParticipantsThis open-label, phase 3 randomized clinical trial was conducted at 77 hospitals in France and Canada and included patients aged 18 to 79 years with histologically confirmed pancreatic ductal adenocarcinoma who had undergone complete macroscopic (R0/R1) resection within 3 to 12 weeks before randomization. Patients were included from April 16, 2012, through October 3, 2016. The cutoff date for this analysis was June 28, 2021.InterventionsA total of 493 patients were randomized (1:1) to receive treatment with modified FOLFIRINOX (oxaliplatin, 85 mg/m2 of body surface area; irinotecan, 150-180 mg/m2; leucovorin, 400 mg/m2; and fluorouracil, 2400 mg/m2, every 2 weeks) or gemcitabine (1000 mg/m2, days 1, 8, and 15, every 4 weeks) as adjuvant therapy for 24 weeks.Main Outcomes and MeasuresPrimary end point was disease-free survival. Secondary end points included overall survival, metastasis-free survival, and cancer-specific survival. Prognostic factors for overall survival were determined.ResultsOf the 493 patients, 216 (43.8%) were women, and the mean (SD) age was 62.0 (8.9) years. At a median of 69.7 months’ follow-up, 367 disease-free survival events were observed. In patients receiving chemotherapy with modified FOLFIRINOX vs gemcitabine, median disease-free survival was 21.4 months (95% CI, 17.5-26.7) vs 12.8 months (95% CI, 11.6-15.2) (hazard ratio [HR], 0.66; 95% CI, 0.54-0.82; P < .001) and 5-year disease-free survival was 26.1% vs 19.0%; median overall survival was 53.5 months (95% CI, 43.5-58.4) vs 35.5 months (95% CI, 30.1-40.3) (HR, 0.68; 95% CI, 0.54-0.85; P = .001), and 5-year overall survival was 43.2% vs 31.4%; median metastasis-free survival was 29.4 months (95% CI, 21.4-40.1) vs 17.7 months (95% CI, 14.0-21.2) (HR, 0.64; 95% CI, 0.52-0.80; P < .001); and median cancer-specific survival was 54.7 months (95% CI, 45.8-68.4) vs 36.3 months (95% CI, 30.5–43.9) (HR, 0.65; 95% CI, 0.51-0.82; P < .001). Multivariable analysis identified modified FOLFIRINOX, age, tumor grade, tumor staging, and larger-volume center as significant favorable prognostic factors for overall survival. Shorter relapse delay was an adverse prognostic factor.Conclusions and RelevanceThe final 5-year results from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial indicate that adjuvant treatment with modified FOLFIRINOX yields significantly longer survival than gemcitabine in patients with resected pancreatic ductal adenocarcinoma.Trial RegistrationEudraCT: 2011-002026-52; ClinicalTrials.gov Identifier: NCT01526135
Annals of surgical oncology · 2019
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The oncologist · 2025 · Journal Article
Evrard C, Pelras A, Rivet S, Bachet JB, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025 · Journal Article
Cotte E, Arquilliere J, Artru P, Bachet JB, et al.
Clinical colorectal cancer · 2025 · Clinical Trial Protocol
Assaf I, Bregni G, Anthoine G, Aparicio T, et al.
European journal of cancer (Oxford, England : 1990) · 2024 · Journal Article
Parisi A, Delaunay B, Pinterpe G, Hollebecque A, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2023 · Journal Article
Coriat R, Sibaud V, Bourgeois V, Manfredi S, et al.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023 · Journal Article
Bergen ES, Pilla L, Auclin E, Ilhan-Mutlu A, et al.
Targeted oncology · 2023 · Journal Article
Neuzillet C, Artru P, Assenat E, Edeline J, et al.
Cancers · 2022 · Journal Article
Roth GS, Fayet Y, Benmameche-Medjahed S, Ducimetière F, et al.
Endoscopic ultrasound · 2022 · Journal Article
Schoch A, Lisotti A, Walter T, Fumex F, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2022 · Journal Article
Gallois C, Hafliger E, Auclin E, Perret A, et al.
World journal of surgical oncology · 2022 · Journal Article
Javed S, Benoist S, Devos P, Truant S, et al.
Clinics and research in hepatology and gastroenterology · 2021 · Journal Article
Gallois C, Bourillon C, Auclin E, Artru P, et al.
Cancers · 2021 · Journal Article
de la Fouchardière C, Adham M, Marion-Audibert AM, Duclos A, et al.
Annals of translational medicine · 2021 · Journal Article
Morgant S, Artru P, Oudjit A, Lourenco N, et al.
European journal of cancer (Oxford, England : 1990) · 2019 · Journal Article
Gallois C, Artru P, Lièvre A, Auclin E, et al.
Annals of surgical oncology · 2019 · Journal Article
Pietrasz D, Turrini O, Vendrely V, Simon JM, et al.
The New England journal of medicine · 2018 · Clinical Trial, Phase III
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, et al.
The Lancet. Oncology · 2025 · Journal Article
Zaanan A, Bouché O, de la Fouchardière C, Le Malicot K, et al.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025 · Clinical Trial Protocol
Lecomte T, Giraudeau B, Phelip JM, Tournigand C, et al.
European journal of cancer (Oxford, England : 1990) · 2024 · Journal Article
M'Baloula J, Tougeron D, Boilève A, Jeanbert E, et al.
Clinical colorectal cancer · 2022 · Journal Article
Coutzac C, Trouilloud I, Artru P, Henriques J, et al.
British journal of cancer · 2022 · Journal Article
Zaibet S, Hautefeuille V, Auclin E, Lièvre A, et al.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024 · Journal Article
François E, Magné N, Boulahssass R, Ronchin P, et al.
European journal of cancer (Oxford, England : 1990) · 2023 · Randomized Controlled Trial
François E, De Bari B, Ronchin P, Nouhaud E, et al.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024 · Journal Article
François E, Magné N, Boulahssass R, Ronchin P, et al.
Clinical colorectal cancer · 2022 · Clinical Trial, Phase II
Bertaut A, Touchefeu Y, Blanc J, Bouché O, et al.
Clinical colorectal cancer · 2020 · Journal Article
Auvray M, Tougeron D, Auclin E, Moulin V, et al.
SupplFig_1_PS – Supplemental material for Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
Supplemental material, SupplFig_1_PS for Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study by Nicolas Williet, Angéliqu
SupplFig_2_Toxicities – Supplemental material for Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
Supplemental material, SupplFig_2_Toxicities for Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study by Nicolas Williet,
SupplFig_2_Toxicities – Supplemental material for Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
Supplemental material, SupplFig_2_Toxicities for Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study by Nicolas Williet,
Folfirinox <i>versus</i> gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
Background:Folfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-line treatments in patients with metastatic pancreatic cancer (mPC). However, data comparing these two chemotherapeutic regimens and
NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)
Abstract Background Preoperative radiochemotherapy (RCT) is recommended in France prior to total mesorectal excision in patients with mid or low locally advanced rectal cancer (LARC) (cT3/T4 and/or N+) because it has bee
SupplFig_1_PS – Supplemental material for Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
Supplemental material, SupplFig_1_PS for Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study by Nicolas Williet, Angéliqu
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
JAMA oncology · 2024 · Clinical Trial, Phase II
Tougeron D, Dahan L, Evesque L, Le Malicot K, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · Journal Article
Nicolle R, Bachet JB, Harlé A, Iovanna J, et al.
European journal of cancer (Oxford, England : 1990) · 2023 · Randomized Controlled Trial
François E, De Bari B, Ronchin P, Nouhaud E, et al.
JAMA oncology · 2022 · Randomized Controlled Trial
Conroy T, Castan F, Lopez A, Turpin A, et al.
Clinical colorectal cancer · 2022 · Clinical Trial, Phase II
Bertaut A, Touchefeu Y, Blanc J, Bouché O, et al.
Journal of geriatric oncology · 2020 · Clinical Trial, Phase II
Aparicio T, Darut-Jouve A, Khemissa Akouz F, Montérymard C, et al.
BMC cancer · 2020 · Clinical Trial Protocol
Brouquet A, Bachet JB, Huguet F, Karoui M, et al.
Clinical colorectal cancer · 2019 · Journal Article
Bennouna J, André T, Campion L, Hiret S, et al.
JAMA oncology · 2019 · Clinical Trial, Phase II
Bennouna J, Hiret S, Bertaut A, Bouché O, et al.
British journal of cancer · 2022 · Published Erratum
Zaibet S, Hautefeuille V, Auclin E, Lièvre A, et al.
Journal of geriatric oncology · 2020 · Clinical Trial, Phase II
Aparicio T, Darut-Jouve A, Khemissa Akouz F, Montérymard C, et al.